Gilead Sciences (GILD) Tops Q3 EPS by 32c; offers guidance

Gilead Sciences (NASDAQ: GILD) reported Q3 EPS of $2.47, $0.32 better than the analyst estimate of $2.15. Revenue for the quarter came in at $7.8 billion versus the consensus estimate of $7.45 billion.

GUIDANCE:

Gilead Sciences sees FY2025 EPS of $8.05-$8.25, versus the consensus of $8.05. Gilead Sciences sees FY2025 Product revenue of $28.4-28.7 billion, versus the consensus of $28.836 billion.

For earnings history and earnings-related data on Gilead Sciences (GILD) click here.

You May Also Be Interested In

• McDonald’s said to plan value strategy overhaul to revive US sales growth
• Huang and Altman to attend Trump-Xi state dinner - ABC
• Ginkgo Bioworks (DNA) 4K contracts of December 11 calls trade, share price up 13.3%